Searching for Innovative Cancer Therapies in Biotech

LAS VEGAS, October 5, 2017 /PRNewswire/ --

Only second to heart disease, cancer is rated the second most common cause of death in the United States. We've all heard of cancer, or had it affect our lives in some way or another, but what do we really know about cancer itself and where are we in the process of finding a cure?

Cancer is a group of diseases distinguished by the growth and spread of abnormal, or malignant cells. What makes cancer so dangerous is when the malignant cells spread uncontrollably. The American Cancer Society reported that almost 1.7 million cancer cases are expected to be diagnosed in 2017 creating a substantial need for effective cancer medication. Investors need to be tracking the leading pharmaceutical and biotechnology companies, especially companies creating therapies to stop the recurrence of tumors and the spreading of malignant cells. With the larger companies like Pfizer, Inc. and Amgen, Inc. in trouble because of the competition among generic key drugs, drug pricing challenges, and increasing competition, focus is changing to smaller innovative biotechs like Propanc Biopharma, Inc. (OTC: PPCB), Kura Oncology, Inc. (NASDAQ: KURA), Moleculin Biotech, Inc. (NASDAQ: MBRX), and ImmunoGen, Inc. (NASDAQ: IMGN), Endocyte, Inc. (NASDAQ: ECYT).

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: $2.01M, current share price: $0.3101 

If you've been keeping an eye on cancer research in biotech, you've heard of PPCB. A clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancer had huge announcements this last week regarding their lead product, PRP. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen which aims to prevent uncontrollable growth and spreading of tumors, the leading cause of death for cancer patients. Results from PPCB's recent scientific experiments provide solid indicators of PRP's therapeutic potential as a new successful clinical approach that could improve outcomes for patients suffering from cancer. This conclusion comes from observing the significant reduction of Epithelial to Mesenchymal Transition (EMT) markers as a consequence of PRP treatment, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of Cancer Stem Cells (CSCs).

Kura Oncology, Inc. (NASDAQ: KURA)

Market Cap: $413.936M, current share price: $14.95 

KURA is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Earlier this month, KURA released favorable results from a Phase 2 trial for its lead product candidate, tipifarnib. They tested their lead product in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment. Keep an eye out on KURA as they move through trials.

Moleculin Biotech, Inc. (NASDAQ: MBRX)

Market Cap: $48.426M, current share price: $2.39 

MBRX is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates. Just this week, MBRX announced that the Food and Drug Administration (FDA) has instructed Moleculin it may begin clinical trials of Annamycin in the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). MBRX currently has two preclinical small molecule portfolios in development, one is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system the other targets the metabolism of tumors.

ImmunoGen, Inc. (NASDAQ: IMGN)

Market Cap: $858.49M, current share price: $7.65 

IMGN is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. IMGN's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer. It's IMGN's mission to deliver innovative cancer therapies that meaningfully improve the lives of patients.

Endocyte, Inc. (NASDAQ: ECYT)

Market Cap: $265.67M, current share price: $6.21 

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company's agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

Email: info@microcapspecualtors.com
Phone: +1-702-720-6310
Website: http://microcapspeculators.com/

For Full Legal Disclaimer Click Here.

DISCLAIMER: MicroCapSpeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns MicroCapSpeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, MicroCapSpeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns MicroCapSpeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
editor@financialnewsmedia.com
(954)345-0611